AC Immune SA (NASDAQ:ACIU) Short Interest Down 8.8% in June

AC Immune SA (NASDAQ:ACIU) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 731,100 shares, a decrease of 8.8% from the June 15th total of 801,400 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average trading volume of 838,900 shares, the short-interest ratio is currently 0.9 days.

Hedge Funds Weigh In On AC Immune

A number of institutional investors have recently made changes to their positions in ACIU. Redmile Group LLC grew its position in AC Immune by 0.4% in the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after acquiring an additional 7,031 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of AC Immune by 96.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock worth $56,000 after purchasing an additional 9,334 shares in the last quarter. Silverberg Bernstein Capital Management LLC bought a new position in shares of AC Immune during the 2nd quarter valued at about $40,000. Finally, Lazard Asset Management LLC bought a new position in shares of AC Immune during the 1st quarter valued at about $30,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Stock Performance

AC Immune stock opened at $3.88 on Wednesday. The stock has a market cap of $383.73 million, a P/E ratio of -5.62 and a beta of 1.27. AC Immune has a fifty-two week low of $2.20 and a fifty-two week high of $5.14. The firm’s fifty day moving average price is $3.84 and its 200-day moving average price is $3.48.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Sell-side analysts predict that AC Immune will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ACIU shares. BTIG Research assumed coverage on AC Immune in a report on Friday, May 31st. They issued a “buy” rating and a $8.00 price target for the company. StockNews.com upgraded AC Immune from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.